Q2 Earnings Estimate for LEXX Issued By Zacks Research

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Research analysts at Zacks Research issued their Q2 2026 earnings per share (EPS) estimates for Lexaria Bioscience in a report issued on Tuesday, February 10th. Zacks Research analyst J. Vandermosten forecasts that the company will post earnings of ($0.07) per share for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share. Zacks Research also issued estimates for Lexaria Bioscience’s Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.26) EPS and FY2027 earnings at ($0.31) EPS.

Lexaria Bioscience (NASDAQ:LEXX) last issued its quarterly earnings data on Tuesday, January 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. Lexaria Bioscience had a negative net margin of 1,685.84% and a negative return on equity of 226.58%. The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.14 million.

A number of other research analysts also recently weighed in on LEXX. Wall Street Zen downgraded shares of Lexaria Bioscience from a “hold” rating to a “sell” rating in a research report on Sunday, December 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Lexaria Bioscience in a research note on Monday, December 29th. Finally, HC Wainwright reduced their price target on Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating for the company in a report on Friday, December 26th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $1.50.

Lexaria Bioscience Stock Performance

Shares of NASDAQ LEXX opened at $0.64 on Thursday. The company has a market capitalization of $15.87 million, a PE ratio of -1.14 and a beta of 0.56. The company’s fifty day moving average price is $0.77 and its 200 day moving average price is $0.92. Lexaria Bioscience has a 1 year low of $0.46 and a 1 year high of $1.90.

Institutional Trading of Lexaria Bioscience

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Byrne Asset Management LLC raised its position in shares of Lexaria Bioscience by 236.8% during the 4th quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock worth $65,000 after purchasing an additional 74,180 shares during the last quarter. Geode Capital Management LLC increased its stake in Lexaria Bioscience by 25.7% during the 4th quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock worth $136,000 after buying an additional 44,939 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Lexaria Bioscience during the 3rd quarter worth approximately $28,000. Hedge funds and other institutional investors own 13.06% of the company’s stock.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.